🔎 Trials Near Me

Domov › Nevroblastom › Kalifornija

Klinične študije za Nevroblastom v Kalifornija

14 študij za Nevroblastom išče udeležence na lokacijah v Kalifornija.

Mesta v Kalifornija

Uradno besedilo študije (angleško)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Kaiser Permanente Downey Medical Center, Downey
  • City of Hope Comprehensive Cancer Center, Duarte
  • Loma Linda University Medical Center, Loma Linda
  • in še 13
Vključevanje udeležencevFaza 3
Do 30 let · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06172296

MCT for the Harvard/UCSF ROBIN Center

  • University of California, San Francisco, San Francisco
Vključevanje udeležencev
Vse starosti · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06000787

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital Los Angeles ( Site 1006), Los Angeles
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Vključevanje udeležencevFaza 2
Do 22 let · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT02559778

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Vključevanje udeležencevFaza 1/2
Do 30 let · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06541262

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Kaiser Permanente Downey Medical Center, Downey
  • Loma Linda University Medical Center, Loma Linda
  • Children's Hospital Los Angeles, Los Angeles
  • in še 9
Vključevanje udeležencevFaza 3
365 Days – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital of Orange County, Orange
  • UCSF Medical Center-Mission Bay, San Francisco
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Vključevanje udeležencevFaza 2
12 Months – 21 Years · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT05489887

SPEARHEAD-3 Pediatric Study

  • Stanford University, Palo Alto
Vključevanje udeležencevFaza 1/2
Starost 2–21 · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT05642455

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, San Francisco, San Francisco
Vključevanje udeležencevFaza 1/2
Starost 1–30 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06721689

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • Children's Hospital Los Angeles, Los Angeles
  • UCSF Benioff Children's Hospital, San Francisco
Vključevanje udeležencevFaza 2
Starost 1–31 · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT06450041

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Lucille Packard Children's Hospital Stanford, Palo Alto
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 19. maj 2026 · NCT04901702

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

  • Stanford University, Palo Alto
Vključevanje udeležencevFaza 1
Starost 2–30 · Vsi spoli · Posodobljeno 7. maj 2026 · NCT06500819

Neuroblastoma Biology Study

  • Children's Hospital Los Angeles, Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Vključevanje udeležencevOpazovalna študija
31 Days – 99 Years · Vsi spoli · Posodobljeno 23. mar. 2026 · NCT01587300

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.